Five years after undergoing transcatheter aortic valve replacement (TAVR), patients with severe aortic stenosis at high or extreme surgical risk who received the first-generation Portico valve system had comparable rates of all-cause mortality or stroke, excellent and sustained mean gradients and mean valve areas, comparable valve durability, and similar improvements in quality of life when compared to similar patients receiving commercially available valves, new trial results show.